ライフサイエンスコーパス: retinal vein occlusion

1 udative age-related macular degeneration, or retinal vein occlusion).

2 edema secondary to either central or branch retinal vein occlusion.

3 egeneration or macular edema attributable to retinal vein occlusion.

4 oliferative diabetic retinopathy and central retinal vein occlusion.

5 s can be an innovative tool in management of retinal vein occlusion.

6 eneration (AMD), diabetic macular edema, and retinal vein occlusion.

7 cular degeneration, diabetic maculopathy, or retinal vein occlusion.

8 n important indicator of disease severity in retinal vein occlusion.

9 eovascularization in the pig model of branch retinal vein occlusion.

10 acular edema, and macular edema secondary to retinal vein occlusion.

11 actor injections in macular edema associated retinal vein occlusion.

12 rosted branch angiitis complicated by branch retinal vein occlusion.

13 acular edema, and macular edema secondary to retinal vein occlusion.

14 hy (SS-OCTA) in grading macular perfusion in retinal vein occlusion.

15 morbidities such as macular degeneration and retinal vein occlusion.

16 y pre-existing diabetic retinopathy (DR) and retinal vein occlusion.

17 ncrease was observed in patients with AMD or retinal vein occlusion.

18 in patients with macular edema secondary to retinal vein occlusion.

19 the importance of systemic evaluation after retinal vein occlusion.

20 he treatment of macular edema due to central retinal vein occlusion.

21 cluded from the therapy approval studies for retinal vein occlusion.

22 and treatment of recurrent macular edema in retinal vein occlusion.

23 quantify macular edema in central and branch retinal vein occlusion.

24 improving visual acuity in participants with retinal vein occlusion.

25 efield angiogram images of eyes with central retinal vein occlusion.

26 ar degeneration, diabetic macular edema, and retinal vein occlusions.

27 ge-related macular degeneration, and central retinal vein occlusions.

28 nsive retinopathy 0.88%, macular scar 0.37%, retinal vein occlusion 0.50%, macular hole 0.20%, retini

29 choroidal detachment (3.0%, n=4) and central retinal vein occlusion (0.7%, n=1).

30 tion (AMD; 42%), diabetic retinopathy (35%), retinal vein occlusions (18%), and neovascular AMD (15%;

31 s in the Study of COmparative Treatments for REtinal Vein Occlusion 2 (SCORE2) and to compare with co

32 d in the Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2) to be noninferior to a

33 s in the Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2).

34 ) in the Study of COmparative Treatments for REtinal Vein Occlusion 2 (SCORE2); evaluate the baseline

35 from the Study of Comparative Treatments for Retinal Vein Occlusion 2 randomized clinical trial inclu

36 d in the Study of Comparative Treatments for Retinal Vein Occlusion 2, and 88 participants randomized

37 phase 3 Study of COmparative Treatments for REtinal Vein Occlusions 2 (SCORE2) clinical trial includ

38 ncluding pars planitis (18 eyes) and central retinal vein occlusion (2 eyes).

39 ration: 34.2 %; diabetic retinopathy: 4.2 %; retinal vein occlusion: 3.8 %).

40 rtery occlusion (4/16), and isolated central retinal vein occlusion (4/16).

41 ction (5 with central and 2 with hemicentral retinal vein occlusion), 4 eyes were unremarkable at pre

42 d by diabetic retinopathy (11 eyes), central retinal vein occlusion (6 eyes), ocular ischemic syndrom

43 tinal artery occlusion and 463 patients with retinal vein occlusion, 66 (58.4%) and 245 (52.9%) were

44 urtscher's retinopathy (4 eyes, 3 patients), retinal vein occlusion (7 eyes, 7 patients), central ret

45 omplete data; concomitant diseases including retinal vein occlusion, age-related macular degeneration

46 was associated with a 40% increased rate of retinal vein occlusion (AIRR 1.4, 95% Confidence Interva

47 contributor to macular edema resulting from retinal vein occlusion, also confirmed in multicenter tr

48 hundred eyes of 100 patients (79 with branch retinal vein occlusion and 21 with central retinal vein

49 derived anatomic measurements between branch retinal vein occlusion and central retinal vein occlusio

50 e main are age-related macular degeneration, retinal vein occlusion and diabetic macular edema.

51 of 50 patients (4%) reported grade 4 events (retinal vein occlusion and embolism).

52 In patients with central retinal vein occlusion and initially low visual acuity,

53 thickness in patients suffering from central retinal vein occlusion and low visual acuity (<0.1) in c

54 sc were made for 13 patients with DE (7 with retinal vein occlusions and 6 with inflammatory optic ne

55 ckings (AVNs) in the retina are the cause of retinal vein occlusions and are also surrogates of cereb

56 ortant implications for the understanding of retinal vein occlusions and of cerebrovascular aging.

57 discussing the prognosis and risk factors of retinal vein occlusions and the treatment options.

58 17 trials (23%) included 3757 patients with retinal vein occlusion, and 1 trial (1%) included 122 pa

59 , diabetic macular edema, central and branch retinal vein occlusion, and miscellaneous causes.

60 , in models of retinal degeneration, central retinal vein occlusion, and oxygen-induced retinopathy.

61 nal vascular diseases, diabetic retinopathy, retinal vein occlusion, and retinal artery occlusion, ma

62 such as proliferative diabetic retinopathy, retinal vein occlusion, and retinal detachment, than in

63 omplication of retinal ischemia in diabetes, retinal vein occlusion, and retinopathy of prematurity.

64 nal diseases including diabetic retinopathy, retinal vein occlusion, and retinopathy of prematurity.

65 n were the number of drug injections, having retinal vein occlusion, and under 60 years of age, while

66 erative diabetic retinopathy), 8.3% to treat retinal vein occlusions, and 12.9% for all other uses.

67 Central and branch retinal vein occlusion are associated with increased ris

68 retinopathy, retinopathy of prematurity and retinal vein occlusion are potentially blinding conditio

69 acentral acute middle maculopathy (PAMM) and retinal vein occlusion are uncommon concurrent findings

70 Although both retinal artery occlusions and retinal vein occlusions are associated with increased ag

71 sive patient, who developed bilateral branch retinal vein occlusion at 6T, the therapy was discontinu

72 betic macular oedema (DME) or branch/central retinal vein occlusion (B/CRVO).

73 patients with diabetic retinal diseases and retinal vein occlusions (both <0.1 per 1000 retinal vein

74 In retinal vein occlusion, both ranibizumab and Ozurdex hav

75 ety outcomes in eyes with branch and central retinal vein occlusion (BRVO and CRVO) treated with dexa

76 The most common type of RVO was branch retinal vein occlusion (BRVO) (53%).

77 Early responder eyes with branched retinal vein occlusion (BRVO) and central retinal vein o

78 tral retinal vein occlusion (CRVO) or branch retinal vein occlusion (BRVO) causes hypoperfusion, high

79 ral retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO) complicated by macular ede

80 was diagnosed in 32 (27.6%) eyes, and branch retinal vein occlusion (BRVO) in 84 (72.4%) eyes.

81 olume distensibility in patients with branch retinal vein occlusion (BRVO) in comparison with normal

82 natural history of visual outcome in branch retinal vein occlusion (BRVO) is fundamental to its mana

83 Branch retinal vein occlusion (BRVO) is one of the most importa

84 Branch retinal vein occlusion (BRVO) is second only to diabetic

85 optic nerve head (ONH) parameters and branch retinal vein occlusion (BRVO) using spectral domain opti

86 venous crossings are risk factors for branch retinal vein occlusion (BRVO), an eye disease in which c

87 R) on metamorphopsia in patients with branch retinal vein occlusion (BRVO), and to assess the relatio

88 ection for macular edema secondary to branch retinal vein occlusion (BRVO).

89 ) for macular edema (ME) secondary to branch retinal vein occlusion (BRVO).

90 ative diabetic retinopathy (PDR), and branch retinal vein occlusion (BRVO).

91 ent due to macular edema secondary to branch retinal vein occlusion (BRVO).

92 retinal disease ("healthy") and with branch retinal vein occlusion (BRVO).

93 macular thickness (CMT) in eyes with branch retinal vein occlusion (BRVO).

94 r edema (ME) recurrences secondary to branch retinal vein occlusion (BRVO).

95 nt of macular edema (ME) secondary to branch retinal vein occlusion (BRVO).

96 pth (VCD) and both central (CRVO) and branch retinal vein occlusions (BRVO) using optical low coheren

97 n occlusion [CRVO]) and 17.4 to 19.1 (branch retinal vein occlusion [BRVO]).

98 d points, AF was not associated with central retinal vein occlusion but was associated with urinary t

99 ab and steroid implants can be considered in retinal vein occlusion, but trials are awaited to determ

100 ration (nAMD), diabetic macular edema (DME), retinal vein occlusion, choroidal neovascularization (CN

101 ular diseases (e.g., diabetic macular edema, retinal vein occlusion, choroidal neovascularization) ha

102 pain score) and similar to patients in other retinal vein occlusion clinical trials.

103 Central and branch retinal vein occlusion cohorts were compared with contro

104 en were associated with an increased rate of retinal vein occlusion compared to non-use, although the

105 uently developed retinal artery occlusion or retinal vein occlusion compared with patients undergoing

106 ataract, uveitis, dry eye disease, glaucoma, retinal vein occlusion, conjunctivitis, meibomian gland

107 ataract, uveitis, dry eye disease, glaucoma, retinal vein occlusion, conjunctivitis, meibomian gland

108 the amount of neovascularization induced by retinal vein occlusion, corneal growth factor pellets, a

109 ng data exists on whether central and branch retinal vein occlusion (CRVO and BRVO) are linked to sys

110 aphy angiography (OCTA) in eyes with central retinal vein occlusion (CRVO) and branch retinal vein oc

111 o review the definition of ischaemic central retinal vein occlusion (CRVO) and stratify the risk of n

112 retinal artery occlusion (CRAO) and central retinal vein occlusion (CRVO) as a complication of persi

113 In the central retinal vein occlusion (CRVO) cohort, univariate and mul

114 ed retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO) have better functional res

115 To determine the outcome of central retinal vein occlusion (CRVO) in pre-existing glaucoma a

116 Central retinal vein occlusion (CRVO) or branch retinal vein occ

117 rticipants with macular edema due to central retinal vein occlusion (CRVO) or hemiretinal vein occlus

118 ents with macular edema secondary to central retinal vein occlusion (CRVO) or hemiretinal vein occlus

119 ble to macular edema associated with central retinal vein occlusion (CRVO) or hemiretinal vein occlus

120 Progression from a mild central retinal vein occlusion (CRVO) to a more severe CRVO was

121 Central retinal vein occlusion (CRVO) was diagnosed in 32 (27.6%

122 fty-five patients with a nonischemic central retinal vein occlusion (CRVO) who were randomized to rec

123 ibe a patient who developed combined central retinal vein occlusion (CRVO), cilioretinal artery occlu

124 To review the clinical picture of central retinal vein occlusion (CRVO), with an emphasis on recen

125 ers a distinctive retinopathy with a central retinal vein occlusion (CRVO)-like appearance.

126 perfused macular edema in eyes with central retinal vein occlusion (CRVO).

127 hemiretinal vein occlusion (HRVO) or central retinal vein occlusion (CRVO).

128 aucoma, such as macular edema due to central retinal vein occlusion (CRVO).

129 r edema (ME) resolution in eyes with central retinal vein occlusion (CRVO).

130 nch retinal (BRVO), hemi-retinal and central retinal vein occlusion (CRVO).

131 CG) in eyes with the recent onset of central retinal vein occlusion (CRVO).

132 id macular oedema (CMO) secondary to central retinal vein occlusion (CRVO).

133 etic macular edema (DME), central and branch retinal vein occlusion (CRVO/BRVO), central serous chori

134 at 6 and 12 months was 15.0 to 16.5 (central retinal vein occlusion [CRVO]) and 17.4 to 19.1 (branch

135 retinopathy, glaucoma, and branch or central retinal vein occlusion diagnosis.

136 e tomography angiography (OCTA) among branch retinal vein occlusion disease (BRVO) cases with macular

137 ve (2/26), and neovascular following central retinal vein occlusion from amyloidosis (1/26).

138 and the absence of such a difference in the retinal vein occlusion group could be explained by edema

139 = 0.024); however, the same analysis in the retinal vein occlusion group revealed no significant dif

140 en branch retinal vein occlusion and central retinal vein occlusion groups (all P >/= 0.058); therefo

141 Patients with retinal vein occlusion had higher risks of hemorrhagic s

142 to 28 % of patients presenting with central retinal vein occlusion have a baseline BCVA of less than

143 eneration (HR = 1.29; 95% CI: 1.08-1.54) and retinal vein occlusion (HR = 3.94; 95% CI: 3.11-4.99).

144 occlusion (HR: 1.13, 95% CI: 1.02-1.26) and retinal vein occlusion (HR: 1.26, 95% CI: 1.20-1.33).

145 86), glaucoma (HR: 1.40, 95% CI: 1.05-1.88), retinal vein occlusion (HR: 1.58, 95% CI: 1.23-2.03), co

146 r managing complications of ischemic central retinal vein occlusion (iCRVO).

147 occlusion manifesting as PAMM and incomplete retinal vein occlusion in a young male adult.

148 ged 18 years with macular edema secondary to retinal vein occlusion in the branch vein occlusion (BRA

149 Retinal vein occlusion is a common retinal vascular diso

150 Central retinal vein occlusion is a variable disease pattern.

151 Retinal ischemic damage associated with retinal vein occlusion is exacerbated by fluid extravasa

152 Retinal vein occlusion is the second most common retinal

153 with stroke expertise, whereas treatment of retinal vein occlusions is provided by ophthalmologists.

154 cation of diabetes mellitus, prematurity, or retinal vein occlusion, is a major cause of blindness wo

155 In eyes with retinal vein occlusion, longer ME duration at the time o

156 ve of best-corrected visual acuity (BCVA) in retinal vein occlusion macular edema (RVO-ME).

157 g, contralateral PCME, diabetic retinopathy, retinal vein occlusion, macular hole, epiretinal membran

158 pressure in the cat after acute experimental retinal vein occlusion may define the role of intravascu

159 macular edema, macular edema associated with retinal vein occlusion, myopic choroidal neovascularizat

160 h retinal arterial occlusion (n = 3), branch retinal vein occlusion (n = 1), vitamin A deficiency (n

161 , diarrhoea, myocardial infarction, pyrexia, retinal vein occlusion, n=1 each; placebo: vomiting, whi

162 Cystoid macular edema in retinal vein occlusion occurred in relation to altered i

163 caused by inflammatory optic neuropathies or retinal vein occlusions on optical coherence tomography

164 jacent retinal arterioles than to blood from retinal vein occlusions or adjacent retinal venules, sug

165 , leakage such as macular edema secondary to retinal vein occlusion, or a combination of proliferatio

166 ulations: those with diabetic macular edema, retinal vein occlusion, or epiretinal membrane.

167 eovascular age-related macular degeneration, retinal vein occlusions, or diabetic macular edema were

168 In very rare cases, acute inflammatory retinal vein occlusion, papillophlebitis or retinopathy

169 This suggests that prompt treatment for retinal vein occlusion, particularly BRVO, may be associ

170 retinal vein occlusions (both <0.1 per 1000 retinal vein occlusion patients in 2011, 5.6 and 140.2 i

171 retrospective chart review was performed on retinal vein occlusion patients treated by three anti-va

172 The increased rate of retinal vein occlusion persisted with use of combined or

173 CE PATTERN(R) GUIDELINES: New evidence-based Retinal Vein Occlusions Preferred Practice Pattern(R) (P

174 RETINAL VEIN OCCLUSIONS PREFERRED PRACTICE PATTERN(R) GU

175 agent ranibizumab in diabetic macular edema, retinal vein occlusion, pseudophakic macular edema, and

176 pathy, age-related macular degeneration, and retinal vein occlusion receiving intravitreal injections

177 (nAMD), diabetic macular edema (DME), branch retinal vein occlusion-related macular edema (BRVO-ME),

178 related macular edema (BRVO-ME), and central retinal vein occlusion-related macular edema (CRVO-ME).

179 diverse conditions as diabetic retinopathy, retinal vein occlusion, retinopathy of prematurity, exud

180 E (RR 19.5), diabetic retinopathy (RR 13.1), retinal vein occlusion (RR 12.9), macular hole (RR 7.7),

181 e (ERM) (RR, 4.1, CI, 2.63-6.19), history of retinal vein occlusion (RR, 2.94, CI, 1.75-4.93), diabet

182 .07), uveitis (RR, 2.88; 95% CI, 1.50-5.51), retinal vein occlusion (RR, 4.47; 95% CI, 2.56-5.92), or

183 oedema (DMO) (542 cases, 66.0%), followed by retinal vein occlusion (RVO) (91 cases, 13.3%).

184 Progression was associated with retinal vein occlusion (RVO) (P < .01), lower median pre

185 clinical profile of patients diagnosed with retinal vein occlusion (RVO) and its correlation with se

186 R), retinopathie of prematurity (ROP) or the retinal vein occlusion (RVO) are caused through a hypoxi

187 he clinical unmet needs in the management of Retinal Vein Occlusion (RVO) associated Macular Edema (M

188 Macular oedema secondary to retinal vein occlusion (RVO) can cause vision loss due t

189 Results of ocular biometric measurements in retinal vein occlusion (RVO) eyes are still inconclusive

190 is study evaluated the treatment outcomes of retinal vein occlusion (RVO) in a routine clinical pract

191 the prevalence, pattern and risk factors of retinal vein occlusion (RVO) in an elderly population of

192 (RNV) and to monitor the dynamic changes of retinal vein occlusion (RVO) in living rabbits.

193 tiation in ranibizumab-treated patients with retinal vein occlusion (RVO) in the SHORE study.

194 the treatment of macular edema secondary to retinal vein occlusion (RVO) in treatment-naive patients

195 Retinal vein occlusion (RVO) is a major cause of vision

196 Macular edema secondary to retinal vein occlusion (RVO) is a sight-threatening cond

197 PURPOSE OF REVIEW: Retinal vein occlusion (RVO) is a sight-threatening reti

198 Macular edema secondary to retinal vein occlusion (RVO) is an important cause of lo

199 Retinal vein occlusion (RVO) is the second most common c

200 ic, and gender composition of the cohorts of retinal vein occlusion (RVO) macular edema (ME) clinical

201 Next, efficacy was also examined in a retinal vein occlusion (RVO) model in which retinal vasc

202 es of 9 patients with either partial central retinal vein occlusion (RVO) or nonischemic RVO.

203 Investigate disparities in retinal vein occlusion (RVO) presentation and initiation

204 ion (AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO) were evaluated by Pearson c

205 ases including diabetic retinopathy (DR) and retinal vein occlusion (RVO) were recruited.

206 sented with no RVD, 20 patients (25.6%) with retinal vein occlusion (RVO), 16 patients (20.5%) with r

207 (AMD), glaucoma, diabetic retinopathy (DR), retinal vein occlusion (RVO), and hypertensive retinopat

208 ses, including diabetic retinopathy (DR) and retinal vein occlusion (RVO), and neovascular macular di

209 lopathy including diabetic retinopathy (DR), retinal vein occlusion (RVO), and neovascular-age relate

210 ents with diabetic retinopathy (DR), AMD and retinal vein occlusion (RVO), and to identify potential

211 Participants were diagnosed with ME from retinal vein occlusion (RVO), diabetic retinopathy (DR;

212 pants (n = 1063) were diagnosed with ME from retinal vein occlusion (RVO), diabetic retinopathy (DR;

213 horoidal neovascularization (CNV) and 1 with retinal vein occlusion (RVO), experienced disease quiesc

214 ve regimen for diabetic macular edema (DME), retinal vein occlusion (RVO), noninfectious uveitis macu

215 ation (AMD), diabetic macular edema (DME) or retinal vein occlusion (RVO), receiving intravitreal tre

216 Individuals were categorized as having retinal vein occlusion (RVO), retinal artery occlusion (

217 in vivo imaging measures in a mouse model of retinal vein occlusion (RVO).

218 eatment of macular edema (ME) resulting from retinal vein occlusion (RVO).

219 genotype, folate and vitamin B12 status, and retinal vein occlusion (RVO).

220 acular edema (DME), and macular edema due to retinal vein occlusion (RVO).

221 s including patients with different types of retinal vein occlusion (RVO).

222 mation may play a role in the development of retinal vein occlusion (RVO).

223 decreased visual acuity (VA) associated with retinal vein occlusion (RVO).

224 fferentiate between ischemic and nonischemic retinal vein occlusion (RVO).

225 l association between COVID-19 infection and retinal vein occlusion (RVO).

226 (CLS-TA), in eyes with macular edema due to retinal vein occlusion (RVO).

227 aturity (ROP), diabetic retinopathy (DR) and retinal vein occlusion (RVO).

228 r treatment of macular edema associated with retinal vein occlusion (RVO).

229 ), diabetic macular edema (DME, n = 400), or retinal vein occlusion (RVO, n = 400) acquired with Zeis

230 sting macular edema (ME) due to diabetes and retinal vein occlusions (RVO) make up a growing populati

231 rative diabetic retinopathy (PDR), 23.3% had retinal vein occlusions (RVO), and the remaining 15.0% s

232 on [nAMD], diabetic macular edema [DME], and retinal vein occlusion [RVO]) through a systematic scopi

233 story of retinal artery occlusions (RAOs) or retinal vein occlusions (RVOs) more than 6 months before

234 condary to AMD or Macular Edema Secondary to Retinal Vein Occlusion, Safety Assessment of Intravitrea

235 The Standard of Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) Study showed that intravi

236 the Standard Care versus COrticosteroid for REtinal Vein Occlusion (SCORE)-CRVO trial, CRUISE Study,

237 hemorrhages and diagnosed as macular branch retinal vein occlusion secondary to hypertension.

238 conditions, including diabetic retinopathy, retinal vein occlusion, sickle cell retinopathy, uveitis

239 The Collaborative Central Retinal Vein Occlusion Study has recently reported infor

240 on in the Standard Care vs Corticosteroid in Retinal Vein Occlusion Study.

241 ercept in Subjects with Macular Edema Due to Retinal Vein Occlusion (TANZANITE) study who received ei

242 2 patients, one each with Eales' disease and retinal vein occlusion the procedure was unsuccessful, n

243 te to progression of retinal nonperfusion in retinal vein occlusion, the same is true in patients wit

244 emorrhages compatible with incomplete branch retinal vein occlusion; the right eye was normal.

245 reference populations and patients in other retinal vein occlusion trials.

246 ORE2) and to compare with cohorts from other retinal vein occlusion trials.

247 rom 13 patients with diabetic retinopathy or retinal vein occlusion underwent both UWF-FA (Optos Silv

248 , and 4 negative control end points (central retinal vein occlusion, urinary tract infection, humeral

249 mic diseases including diabetic retinopathy, retinal vein occlusion, uveitis, and HIV-related retinit

250 In retinal vein occlusion, venous pressures in a segmental

251 Central retinal vein occlusion was associated with an overall in

252 Branch retinal vein occlusion was associated with increased ris

253 Central retinal vein occlusion was associated with increased ris

254 Retinal vein occlusion was observed in some Cbs(+/-) mou

255 tinal artery occlusion and 463 patients with retinal vein occlusion were enrolled and matched for age

256 two patients with macular edema secondary to retinal vein occlusion were enrolled in the study.

257 ar edema (ME) due to diabetic retinopathy or retinal vein occlusion were evaluated.

258 In 20 eyes of 10 pigs, branch retinal vein occlusions were created in a standardized m

259 Retinal vein occlusions were further divided into branch

260 h retinal vein occlusion and 21 with central retinal vein occlusion) were recruited in the study.

261 e patients, 3 with branch and 9 with central retinal vein occlusion, were imaged in 27 sessions with

262 tic neuropathy in contrast to what occurs in retinal vein occlusion, where edema affects all retinal

263 eyes with macular edema secondary to central retinal vein occlusion, which were treated with a dexame

264 Central retinal vein occlusion with high-intensity treatment was

265 Treatment of macular edema secondary to retinal vein occlusion with ranibizumab has been shown t

266 rysm with subretinal hemorrhage (1), central retinal vein occlusion with vitreous hemorrhage (1), and